UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1833 Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country

European journal of cancer (1990), 2015-09, Vol.51, p.S276-S277

2015

Volltextzugriff (PDF)

OC-0253: Mid-treatment adaptive dosimetry of swallowing organs at risk(SWOAR) in head & neck cancer patients undergoing VMAT

Radiotherapy and oncology, 2013-03, Vol.106, p.S99-S99

2013

Volltextzugriff (PDF)

OP0007 What if all cancer patients in Malaysia had access to the best available care: How many deaths are avoidable?

European journal of cancer (1990), 2014-05, Vol.50, p.e2-e3

2014

Volltextzugriff (PDF)

The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer

The surgeon (Edinburgh), 2008-08, Vol.6 (4), p.222-231

2008

Volltextzugriff (PDF)

PD-0084 EFFECTS OF MRI SCAN POSITION ON CT IMAGE REGISTRATION AND TARGET DELINEATION FOR OROPHARYNX CANCER VMAT PATIENTS

Radiotherapy and oncology, 2012-05, Vol.103, p.S33-S34

2012

Volltextzugriff (PDF)

Trastuzumab-related Palmar Plantar Erythrodysaesthesia

Clinical oncology (Royal College of Radiologists (Great Britain)), 2012-02, Vol.24 (1), p.80-81

2012

Volltextzugriff (PDF)

362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial

Annals of oncology, 2022-11, Vol.33, p.S1582-S1583

2022

Volltextzugriff (PDF)

1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study

Annals of oncology, 2023-10, Vol.34, p.S771-S771

2023

Volltextzugriff (PDF)

Oesophageal Toxicity and Hypofractionated Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2009-02, Vol.21 (1), p.74-74

2009

Volltextzugriff (PDF)

P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S352-S353

2023

Volltextzugriff (PDF)

566P Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib

Annals of oncology, 2023-11, Vol.34, p.S1691

2023

Volltextzugriff (PDF)

1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC

Annals of oncology, 2023-10, Vol.34, p.S780-S781

2023

Volltextzugriff (PDF)

EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S483-S484

2022

Volltextzugriff (PDF)

364P Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series

Annals of oncology, 2022-11, Vol.33, p.S1584

2022

Volltextzugriff (PDF)

OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S94

2023

Volltextzugriff (PDF)

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

Annals of oncology, 2022-09, Vol.33, p.S1419-S1420

2022

Volltextzugriff (PDF)

1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2

Annals of oncology, 2021-09, Vol.32, p.S1036-S1036

2021

Volltextzugriff (PDF)

Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis

Oncogene, 2012-03, Vol.31 (11), p.1366-1375

2012

Volltextzugriff (PDF)

Guillain–Barre syndrome occurring after adjuvant chemo-radiotherapy for endometrial cancer

Gynecologic oncology, 2006-03, Vol.100 (3), p.615-617

2006

Volltextzugriff (PDF)

Unusual metastases from malignant pleural mesothelioma

Clinical oncology (Royal College of Radiologists (Great Britain)), 2005-06, Vol.17 (4), p.293-293

2005

Volltextzugriff (PDF)

Acute Supraclavicular Skin Toxicity in Patients Undergoing Radiotherapy for Breast Cancer: An Evaluation of the ‘T’-Grip Method of Patient Positioning

Clinical oncology (Royal College of Radiologists (Great Britain)), 2006-03, Vol.18 (2), p.133-138

2006

Volltextzugriff (PDF)

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.324-343

2020

Volltextzugriff (PDF)

A simple sketch for 3D scanning based on a rotating platform and a Web camera

Proceedings. XV Brazilian Symposium on Computer Graphics and Image Processing, 2002, p.406

2002

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(23)
Tagungsberichte
(1)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

1833 Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country

OC-0253: Mid-treatment adaptive dosimetry of swallowing organs at risk(SWOAR) in head & neck cancer patients undergoing VMAT

OP0007 What if all cancer patients in Malaysia had access to the best available care: How many deaths are avoidable?

The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer

PD-0084 EFFECTS OF MRI SCAN POSITION ON CT IMAGE REGISTRATION AND TARGET DELINEATION FOR OROPHARYNX CANCER VMAT PATIENTS

Trastuzumab-related Palmar Plantar Erythrodysaesthesia

362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial

1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study

Oesophageal Toxicity and Hypofractionated Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer

P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study

566P Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib

1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC

Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial

EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

364P Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series

OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2

Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis

Guillain–Barre syndrome occurring after adjuvant chemo-radiotherapy for endometrial cancer

Unusual metastases from malignant pleural mesothelioma

Acute Supraclavicular Skin Toxicity in Patients Undergoing Radiotherapy for Breast Cancer: An Evaluation of the ‘T’-Grip Method of Patient Positioning

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

A simple sketch for 3D scanning based on a rotating platform and a Web camera

Suchergebnisse filtern